Therapeutic Response

ER negative, HER2-negative, PD-L1 >= 1%, and PR negative status confers therapeutic sensitivity to Atezolizumab in combination with Nab-paclitaxel in patients with Invasive Breast Carcinoma.

Statements

Source and description
Atezolizumab and nab-PACLitaxel Therapy. NCCP National SACT Regimen. HSE. The Republic of Ireland's Health Service Executive (HSE) has approved atezolizumab in combination with nab-paclitaxel for reimbursement as a treatment option for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumors have PD-L1 expression >= 1% and who have not received prior chemotherapy for metastatic disease.
Tecentriq (atezolizumab) [product information]. EMA. The European Medicines Agency (EMA) has authorized atezolizumab in combination with nab-paclitaxel for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer whose tumors have PD-L1 expression >= 1% and who have not received prior chemotherapy for metastatic disease.